OptimizeRx (OPRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on OptimizeRx (OPRX) is Neutral.

The composite score behind that read is +0.06, weighing +0.26 of bullish evidence against -0.28 bearish.

OptimizeRx last closed at $8.28, -1.19% on the session.

Against the IVW growth benchmark the position is -1.99% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

19 graded predictions for OPRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks OptimizeRx in the 22nd percentile on valuation and the 46th percentile on return on equity, where 100 is best.

OptimizeRx is classified under Health Care / Health Care Technology, with a market capitalisation of $157.85M.

StockMap tracks OptimizeRx as the 15th largest of the 20 companies it covers in the Health Care Technology industry, part of the Health Care sector.

Across that group the current two-week reads are 14 Neutral, 5 Moderate Underperform and 1 Moderate Outperform.

On that composite OptimizeRx ranks 7th of 20 in the group, against a group median of +0.01.